文献速递神经免疫

多发性硬化患者血清神经丝轻链与影像学疾病活动的时间关系

Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
PubMed 文献 · Neurology · 2024-04-22

在RESTORE试验中,复发型多发性硬化患者随机继续或停用那他珠单抗,每4周评估血清神经丝轻链(sNfL)与钆增强(Gd+)病灶。sNfL在有Gd+病灶者中升高更多,但65例有Gd+病灶者中46例(71%)未超过无Gd+病灶组的95百分位阈值,且sNfL升高通常滞后于Gd+病灶出现。

要点

  • 有Gd+病灶者sNfL自基线至最大值平均变化12.1 pg/mL,无Gd+病灶者为3.2 pg/mL(p=0.003)。
  • Gd+病灶数量越多,sNfL峰值中位变化越大,1、2-3、4-9、≥10个病灶组分别为1.4、3.0、4.3、19.6 pg/mL。
  • 65例有Gd+病灶者中46例(71%)sNfL未超过无Gd+病灶组的95百分位阈值。

核心结论

  • sNfL与Gd+病灶存在相关性,但多数有Gd+病灶的参与者sNfL水平并未升高,这对sNfL作为监测多发性硬化疾病活动生物标志物的使用和解读有启示。

研究设计与样本

  • RESTORE试验(NCT01071083)为随机对照试验,纳入接受那他珠单抗≥12个月的复发型多发性硬化患者,随机继续或停用那他珠单抗,每4周进行MRI和采血至第28周,并在第52周再次评估。
  • 175例入组RESTORE的患者中,166例有血清样本用于分析。

主要发现

  • 有Gd+病灶者较无Gd+病灶者更年轻(37.7岁 vs 43.1岁,p=0.001),基线扩展残疾状态量表评分更低(2.7 vs 3.4,p=0.017)。
  • 有Gd+病灶者(n=65)sNfL自基线至最大值平均变化12.1 pg/mL,无Gd+病灶者(n=101)为3.2 pg/mL(p=0.003)。
  • 随着Gd+病灶数量增加,sNfL峰值中位变化在1个(n=12)、2-3个(n=18)、4-9个(n=21)、≥10个(n=14)病灶组分别增加1.4、3.0、4.3、19.6 pg/mL。
  • 65例有Gd+病灶者中46例(71%)sNfL未升高至超过无Gd+病灶组的95百分位阈值。
  • sNfL的初始升高通常滞后于首次观察到Gd+病灶,sNfL峰值升高出现在首次Gd+病灶出现后中位8周(四分位距0-12周)。

临床怎么用

  • 作者认为,这些观察对sNfL作为生物标志物在对照试验和临床实践中监测多发性硬化疾病活动的使用和解读有启示。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Serum neurofilament light chain (sNfL) levels correlate with multiple sclerosis (MS) disease activity, but the dynamics of this correlation are unknown. We evaluated the relationship between sNfL levels and radiologic MS disease activity through monthly assessments during the 24-week natalizumab treatment interruption period in RESTORE (NCT01071083). METHODS: In the RESTORE trial, participants with relapsing forms of MS who had received natalizumab for ≥12 months were randomized to either continue or stop natalizumab and followed with MRI and blood draws every 4 weeks to week 28 and again at week 52 The sNfL was measured, and its dynamics were correlated with the development of gadolinium-enhancing (Gd+) lesions. Log-linear trend in sNfL levels were modeled longitudinally using generalized estimating equations with robust variance estimator from baseline to week 28. RESULTS: Of 175 patients enrolled in RESTORE, 166 had serum samples for analysis. Participants with Gd+ lesions were younger (37.7 vs 43.1, p = 0.001) and had lower Expanded Disability Status Scale scores at baseline (2.7 vs 3.4, p = 0.017) than participants without Gd+ lesions. sNfL levels increased in participants with Gd+ lesions (n = 65) compared with those without (n = 101, mean change from baseline to maximum sNfL value, 12.1 vs 3.2 pg/mL, respectively; p = 0.003). As the number of Gd+ lesions increased, peak median sNfL change also increased by 1.4, 3.0, 4.3, and 19.6 pg/mL in the Gd+ lesion groups of 1 (n = 12), 2-3 (n = 18), 4-9 (n = 21), and ≥10 (n = 14) lesions, respectively. However, 46 of 65 (71%) participants with Gd+ lesions did not increase above the 95th percentile threshold of the group without Gd+ lesions. The initial increase of sNfL typically trailed the first observation of Gd+ lesions, and the peak increase in sNfL was a median [interquartile range] of 8 [0, 12] weeks after the first appearance of the Gd+ lesion. DISCUSSION: Although sNfL correlated with the presence of Gd+ lesions, most participants with Gd+ lesions did not have elevations in sNfL levels. These observations have implications for the use and interpretation of sNfL as a biomarker for monitoring MS disease activity in controlled trials and clinical practice.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Fox RJ, Cree BAC, de Sèze J, et al. Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis. Neurology. 2024. PMID: 38648580. doi:10.1212/WNL.0000000000209357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。